Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03LGX
|
|||
| Former ID |
DIB001694
|
|||
| Drug Name |
NI-105
|
|||
| Synonyms |
Tau protein modulator (neurodegenerative disease); Tau protein modulator (neurodegenerative disease), Biogen Idec; Tau protein modulator (neurodegenerative disease), Neurimmune Therapeutics
Click to Show/Hide
|
|||
| Indication | Neurodegenerative disorder [ICD-11: 8A20-8A23] | Investigative | [1] | |
| Company |
Neurimmune Therapeutics AG
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H15F3N2O3
|
|||
| Canonical SMILES |
CC1=C(C(C(=C(N1)C)[N+](=O)[O-])C2=CC=CC=C2C(F)(F)F)C(=O)C
|
|||
| InChI |
1S/C16H15F3N2O3/c1-8-13(10(3)22)14(15(21(23)24)9(2)20-8)11-6-4-5-7-12(11)16(17,18)19/h4-7,14,20H,1-3H3
|
|||
| InChIKey |
YYIGWZQIEFYARO-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Microtubule-associated protein tau (MAPT) | Target Info | Modulator | [1] |
| KEGG Pathway | MAPK signaling pathway | |||
| Alzheimer's disease | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| EGFR1 Signaling Pathway | ||||
| Pathway Interaction Database | LPA receptor mediated events | |||
| Reelin signaling pathway | ||||
| Reactome | Caspase-mediated cleavage of cytoskeletal proteins | |||
| WikiPathways | Notch Signaling Pathway | |||
| IL-2 Signaling Pathway | ||||
| MAPK Signaling Pathway | ||||
| Copper homeostasis | ||||
| Kit receptor signaling pathway | ||||
| BDNF signaling pathway | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Alzheimers Disease | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| Apoptotic execution phase | ||||
| IL-5 Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.